Contrasting Cytokinetics (CYTK) & The Competition
Cytokinetics (NASDAQ: CYTK) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Cytokinetics to related businesses based on the strength of its valuation, profitability, risk, institutional ownership, earnings, analyst recommendations and dividends.
Institutional & Insider Ownership
73.7% of Cytokinetics shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 7.2% of Cytokinetics shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Cytokinetics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cytokinetics||$106.41 million||$16.45 million||-4.70|
|Cytokinetics Competitors||$284.28 million||$34.29 million||135.41|
Cytokinetics’ rivals have higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Cytokinetics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations and price targets for Cytokinetics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cytokinetics presently has a consensus target price of $17.90, indicating a potential upside of 129.49%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.16%. Given Cytokinetics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Cytokinetics is more favorable than its rivals.
Risk and Volatility
Cytokinetics has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Cytokinetics’ rivals have a beta of 5.96, indicating that their average share price is 496% more volatile than the S&P 500.
Cytokinetics beats its rivals on 7 of the 12 factors compared.
Cytokinetics Company Profile
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.
Receive News & Ratings for Cytokinetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.